Treatment of Metastatic Renal Cell Carcinoma with Checkpoint Inhibitors in Clinical Practice in the Volga-Ural Region of the Eurasian Continent

CONCLUSION: In this single-center clinical study, we discuss the results of using nivolumab as mono-therapy and the combination of nivolumab with ipilimumab in metastatic renal parenchyma cancer patients.PMID:38037838 | DOI:10.2174/0113816128262498231122072050

Source: Current Pharmaceutical Design - December 1, 2023 Category: Drugs & Pharmacology Authors: Radmir R Rakhimov Aleksandr V Sultanbaev Adel A Izmailov Konstantin V Menshikov Vadim M Zabelin Albert A Izmailov Gulshat R Gilyazova Svetlana M Izmailova Ksenia S Bakhtiyarova Izmailova Angelina Irina R Gilyazova Source Type: research